Continuous cell lines as a production system for influenza vaccines

References

• Gerdil C. The annual production cycle for influenza vaccine. Vaccine21(16), 17761779 (2003).
   PubMed Web of Science ®Google Scholar
• Wood JM, Levandowski RA. The influenza vaccine licensing process. Vaccine21(16), 17861788 (2003).
   PubMed Web of Science ®Google Scholar
• Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine25(27), 49834984 (2007).
   PubMed Web of Science ®Google Scholar
• Hu AY, Weng TC, Tseng YF et al. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines. Vaccine26(45), 57365740 (2008).
   PubMed Web of Science ®Google Scholar
• Howard MK, Kistner O, Barrett PN. Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines. Biol. Chem.389(5), 569577 (2008).
   PubMed Web of Science ®Google Scholar
• Horimoto T, Kawaoka Y. Strategies for developing vaccines against H5N1 influenza A viruses. Trends Mol. Med.12(11), 506514 (2006).
   PubMed Web of Science ®Google Scholar
• Ozawa M, Goto H, Horimoto T, Kawaoka Y. An adenovirus vector-mediated reverse genetics system for influenza A virus generation. J. Virol.81(17), 95569559 (2007).
   PubMed Web of Science ®Google Scholar
• Gabriel G, Garn H, Wegmann M et al. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine26(7), 956965 (2008).
   PubMed Web of Science ®Google Scholar
• Kemble G, Greenberg H. Novel generations of influenza vaccines. Vaccine21(16), 17891795 (2003).
   PubMed Web of Science ®Google Scholar
• Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine27(36), 49754982 (2009).
   PubMed Web of Science ®Google Scholar
• Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine27(5), 748756 (2009).
   PubMed Web of Science ®Google Scholar
• Cox MM, Hollister JR. FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals37(3), 182189 (2009).
   PubMed Web of Science ®Google Scholar
• Palese P. Making better influenza virus vaccines? Emerg. Infect. Dis.12(1), 6165 (2006).
   PubMed Web of Science ®Google Scholar
• Makizumi K, Kimachi K, Fukada K et al. Timely production of A/Fujian-like influenza vaccine matching the 2003–2004 epidemic strain may have been possible using Madin–Darby canine kidney cells. Vaccine26(52), 68526858 (2008).
   PubMed Web of Science ®Google Scholar
• Minor PD, Engelhardt OG, Wood JM et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine27(22), 29072913 (2009).
   PubMed Web of Science ®Google Scholar
• Nicolson C, Major D, Wood JM, Robertson JS. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine23(22), 29432952 (2005).
   PubMed Web of Science ®Google Scholar
• Palker T, Kiseleva I, Johnston K et al. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants. Virus Res.105(2), 183194 (2004).
   PubMed Web of Science ®Google Scholar
• Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi. Viruses2(6), 193202 (2008).
   PubMed Web of Science ®Google Scholar
• Rudenko L, Desheva J, Korovkin S et al. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (Phase III clinical trials). Influenza Other Respi. Viruses2(6), 203209 (2008).
   PubMed Web of Science ®Google Scholar
• Aunins JG. Viral vaccine production in cell culture. In: Encyclopedia of Cell Technology. Spier RE (Ed.). Wiley & Sons, NY, USA, 11821217 (2000).
   Google Scholar
• Lubiniecki AS. Continuous cell substrate considerations. Bioprocess Technol.10, 495513 (1990).
   PubMedGoogle Scholar
• WHO. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting. Bull. World Health Organ.73, 431435 (1995).
   PubMed Web of Science ®Google Scholar
• Madin SH, Darby NB Jr. Established kidney cell lines of normal adult bovine and ovine origin. Proc. Soc. Exp. Biol. Med.98(3), 574576 (1958).
   PubMed Web of Science ®Google Scholar
• Cordat E. Unraveling trafficking of the kidney anion exchanger 1 in polarized MDCK epithelial cells. Biochem. Cell Biol.84(6), 949959 (2006).
   PubMed Web of Science ®Google Scholar
• Simmons NL. Cultured monolayers of MDCK cells: a novel model system for the study of epithelial development and function. Gen. Pharmacol.13(4), 287291 (1982).
   PubMedGoogle Scholar
• Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D. Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine19(2526), 34443450 (2001).
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan GF, Baars M, Claas EC, Osterhaus AD. Comparison of RNA hybridization, hemagglutination assay, titration of infectious virus and immunofluorescence as methods for monitoring influenza virus replication in vitro. J. Virol. Methods74(1), 5766 (1998).
   PubMed Web of Science ®Google Scholar
• Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu® (Novartis vaccines). Expert Rev. Vaccines8(6), 679688 (2009).
   PubMed Web of Science ®Google Scholar
• Genzel Y, Behrendt I, Konig S, Sann H, Reichl U. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine22(17–18), 22022208 (2004).
   PubMed Web of Science ®Google Scholar
• Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine27(46), 64606463 (2009).
   PubMed Web of Science ®Google Scholar
• Genzel Y, Fischer M, Reichl U. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine24(16), 32613272 (2006).
   PubMed Web of Science ®Google Scholar
• Genzel Y, Olmer RM, Schafer B, Reichl U. Wave microcarrier cultivation of MDCK cells for influenza virus production in serum containing and serum-free media. Vaccine24(35–36), 60746087 (2006).
   PubMed Web of Science ®Google Scholar
• Bock A, Reichl U. Closed loop control of perfusion systems in high-density cell culture. In: Cell Technology for Cell Products, 19th ESACT Meeting. Smith R (Ed.). Springer, Harrogate, UK, 549551 (2005).
   Google Scholar
• Schulze-Horsel J, Schulze M, Agalaridis G, Genzel Y, Reichl U. Infection dynamics and virus-induced apoptosis in cell culture-based influenza vaccine production – flow cytometry and mathematical modeling. Vaccine27(20), 27122722 (2009).
   PubMed Web of Science ®Google Scholar
• Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis.176(Suppl. 1), S20S23 (1997).
   Web of Science ®Google Scholar
• Gregersen JP. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine26(26), 33323340 (2008).
   PubMed Web of Science ®Google Scholar
• Gregersen JP. A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines. Vaccine26(26), 32973304 (2008).
   PubMed Web of Science ®Google Scholar
• Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine27(5), 786791 (2009).
   PubMed Web of Science ®Google Scholar
• Polymenidou M, Trusheim H, Stallmach L et al. Canine MDCK cell lines are refractory to infection with human and mouse prions. Vaccine26(21), 26012614 (2008).
   PubMed Web of Science ®Google Scholar
• Halperin SA, Smith B, Mabrouk T et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine20(7–8), 12401247 (2002).
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis.200(6), 849857 (2009).
   PubMed Web of Science ®Google Scholar
• Oh DY, Barr IG, Mosse JA, Laurie KL. MDCK–SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J. Clin. Microbiol.46(7), 21892194 (2008).
   PubMed Web of Science ®Google Scholar
• Murakami S, Horimoto T, Mai LQ et al. Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells. J. Virol.82(21), 1050210509 (2008).
   PubMed Web of Science ®Google Scholar
• Murakami S, Horimoto T, Yamada S, Kakugawa S, Goto H, Kawaoka Y. Establishment of canine RNA polymerase I-driven reverse genetics for influenza A virus: its application for H5N1 vaccine production. J. Virol.82(3), 16051609 (2008).
   PubMed Web of Science ®Google Scholar
• Wang Z, Duke GM. Cloning of the canine RNA polymerase I promoter and establishment of reverse genetics for influenza A and B in MDCK cells. Virol. J.4, 102 (2007).
   PubMed Web of Science ®Google Scholar
• Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H. Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor. J. Biotechnol.121(2), 261271 (2006).
   PubMed Web of Science ®Google Scholar
• Rourou S, van der Ark A, van der Velden T, Kallel H. A microcarrier cell culture process for propagating rabies virus in Vero cells grown in a stirred bioreactor under fully animal component free conditions. Vaccine25(19), 38793889 (2007).
   PubMed Web of Science ®Google Scholar
• Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev. Vaccines8(5), 607618 (2009).
   PubMed Web of Science ®Google Scholar
• Youil R, Su Q, Toner TJ et al. Comparative study of influenza virus replication in Vero and MDCK cell lines. J. Virol Methods120(1), 2331 (2004).
   PubMed Web of Science ®Google Scholar
• Wu SC, Huang GYL. Hydrodynamic shear forces increase Japanese encephalitis virus production from microcarrier-grown Vero cells. Bioprocess Engineering23(3), 229233 (2000).
   Google Scholar
• Wu SC. Influence of hydrodynamic shear stress on microcarrier-attached cell growth: cell line dependency and surfactant protection. Bioprocess Engineering21(3), 201206 (1999).
   Google Scholar
• Kistner O, Howard MK, Spruth M et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine25(32), 60286036 (2007).
   PubMed Web of Science ®Google Scholar
• Desmyter J, Melnick JL, Rawls WE. Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J. Virol.2(10), 955961 (1968).
   PubMed Web of Science ®Google Scholar
• Schwarzer J, Rapp E, Hennig R et al. Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine27(32), 43254336 (2009).
   PubMed Web of Science ®Google Scholar
• Opitz L, Salaklang J, Buttner H, Reichl U, Wolff MW. Lectin-affinity chromatography for downstream processing of MDCK cell culture derived human influenza A viruses. Vaccine25(5), 939947 (2007).
   PubMed Web of Science ®Google Scholar
• Nishiyama K, Sugawara K, Nouchi T et al. Purification and cDNA cloning of a novel protease inhibitor secreted into culture supernatant by MDCK cells. Biologicals36(2), 122133 (2008).
   PubMed Web of Science ®Google Scholar
• Kaverin NV, Webster RG. Impairment of multicycle influenza virus growth in Vero (WHO) cells by loss of trypsin activity. J. Virol.69(4), 27002703 (1995).
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine16(910), 960968 (1998).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Fritsch S et al. A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J. Infect. Dis.200(7), 11131118 (2009).
   PubMed Web of Science ®Google Scholar
• Ueda M, Yamate M, Du A et al. Maturation efficiency of viral glycoproteins in the ER impacts the production of influenza A virus. Virus Res.136(1–2), 9197 (2008).
   PubMed Web of Science ®Google Scholar
• Marjuki H, Scholtissek C, Yen HL, Webster RG. CK2β gene silencing increases cell susceptibility to influenza A virus infection resulting in accelerated virus entry and higher viral protein content. J. Mol. Signal.3, 13 (2008).
   PubMedGoogle Scholar
• Bradel-Tretheway BG, Kelley Z, Chakraborty-Sett S, Takimoto T, Kim B, Dewhurst S. The human H5N1 influenza A virus polymerase complex is active in vitro over a broad range of temperatures, in contrast to the WSN complex, and this property can be attributed to the PB2 subunit. J. Gen. Virol.89(Pt 12), 29232932 (2008).
   PubMed Web of Science ®Google Scholar
• Daidoji T, Koma T, Du A et al. H5N1 avian influenza virus induces apoptotic cell death in mammalian airway epithelial cells. J. Virol.82(22), 1129411307 (2008).
   PubMed Web of Science ®Google Scholar
• Vester D, Rapp E, Gade D, Genzel Y, Reichl U. Quantitative analysis of cellular proteome alterations in human influenza A virus-infected mammalian cell lines. Proteomics9(12), 33163327 (2009).
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Bout A, van der Velde I et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther.9(13), 19091917 (1998).
   PubMed Web of Science ®Google Scholar
• Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine19(17–19), 27162721 (2001).
   PubMed Web of Science ®Google Scholar
• Cox RJ, Madhun AS, Hauge S et al. A Phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine27(13), 18891897 (2009).
   PubMed Web of Science ®Google Scholar
• Koudstaal W, Hartgroves L, Havenga M et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics. Vaccine27(19), 25882593 (2009).
   PubMed Web of Science ®Google Scholar
• Berdichevsky M, Gentile MP, Hughes B et al. Establishment of higher passage PER.C6 cells for adenovirus manufacture. Biotechnol. Prog.24(1), 158165 (2008).
   PubMed Web of Science ®Google Scholar
• Smith KA, Colvin CJ, Weber PS, Spatz SJ, Coussens PM. High titer growth of human and avian influenza viruses in an immortalized chick embryo cell line without the need for exogenous proteases. Vaccine26(29–30), 37783782 (2008).
   PubMed Web of Science ®Google Scholar
• Seo SH, Goloubeva O, Webby R, Webster RG. Characterization of a porcine lung epithelial cell line suitable for influenza virus studies. J. Virol.75(19), 95179525 (2001).
   PubMed Web of Science ®Google Scholar
• Ogura H, Fujiwara T. Establishment and characterization of a virus-free chick cell-line. Acta Medica Okayama41(3), 141143 (1987).
   PubMed Web of Science ®Google Scholar
• Audsley JM, Tannock GA. The growth of attenuated influenza vaccine donor strains in continuous cell lines. J. Virol. Methods123(2), 187193 (2005).
   PubMed Web of Science ®Google Scholar
• Mendonca RZ, Arrozio SJ, Antoniazzi MM, Ferreira JM Jr, Pereira CA. Metabolic active-high density VERO cell cultures on microcarriers following apoptosis prevention by galactose/glutamine feeding. J. Biotechnol.97(1), 1322 (2002).
   PubMed Web of Science ®Google Scholar
• Quesney S, Marc A, Gerdil C et al. Kinetics and metabolic specificities of Vero cells in bioreactor cultures with serum-free medium. Cytotechnology42(1), 111 (2003).
   PubMed Web of Science ®Google Scholar